$COSM

Cosmos Health Inc.

Insider trades
4
0
1

No SEC Form 4 filings for $COSM in the last 30 days.

See all $COSM insider activity →
Med

Cosmos Health Inc. (COSM): Results of Operations and Financial Condition

Cosmos Health Inc. (COSM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cosm_ex991.htm PRESS RELEASE cosm_ex991.htm EXHIBIT 99.1 Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurcha

Cosmos Health Inc.: Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than

Cosmos Health Inc. (COSM) signed an exclusive 5-year distribution agreement with Innova Healthcare for its Sky Premium Life supplements in Saudi Arabia. The deal includes an initial 126,000-unit order and expects over 5 million units in 5 years. Innova operates 250+ pharmacies and is backed by major investors. The Saudi nutraceuticals market is valued at $3.26B, growing to $5.96B by 2033.

COSM sentiment & insider activity

Over the past 7 days, alphai's AI scored 5 news stories mentioning COSM (Cosmos Health Inc.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 1 bearish.

Recent COSM coverage spans corporate actions, earnings and financial news.

What's driving COSM

alphai scores every news story that mentions COSM with an AI model for sentiment and relevance, and aggregates insider trades from Cosmos Health Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $COSM

Score
$COSMMed

Cosmos Health Inc. (COSM): Results of Operations and Financial Condition

Cosmos Health Inc. (COSM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cosm_ex991.htm PRESS RELEASE cosm_ex991.htm EXHIBIT 99.1 Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurcha

Cosmos Health Inc.: Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than

Cosmos Health Inc. (COSM) signed an exclusive 5-year distribution agreement with Innova Healthcare for its Sky Premium Life supplements in Saudi Arabia. The deal includes an initial 126,000-unit order and expects over 5 million units in 5 years. Innova operates 250+ pharmacies and is backed by major investors. The Saudi nutraceuticals market is valued at $3.26B, growing to $5.96B by 2033.

$COSMMed

Cosmos Net Loss Widens In Q2 Despite Revenue Growth

Cosmos Health Inc. (COSM) reported a wider net loss of $6.09M in Q2 2026, up from $2.83M in Q2 2025, due to higher fair value expenses and interest costs, despite a 28.8% revenue increase to $18.99M. Adjusted EBITDA loss narrowed. The company expanded product lines and secured potential financing. Cash position was $2.44M. Shares fell 6.58% to $0.19.

Cosmos Health Inc.: Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders'

Cosmos Health reported Q2 2026 revenue of $19.0M, up 29% YoY, with adjusted gross profit increasing 58%. Total liabilities decreased 13%, and stockholders' equity rose 12%. The company's share repurchase program is active, with 5.1M shares repurchased so far. Revenue growth was driven by all core segments, including Decahedron, Cana Laboratories, and CosmoFarm.

Cosmos Health Inc.: Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units

Cosmos Health (NASDAQ:COSM) said it expanded its Sky Premium Life distribution partnership with Pharma Cell in Albania. Average monthly orders already exceed 4,500 units, and annualized orders are projected to top 54,000. The products are distributed nationwide via Pharma Cell’s network and recommended by doctors and healthcare professionals.

$COSMLow

Cosmos Health Inc. (COSM): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Cosmos Health Inc. (COSM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. cosm_8k.htm 0001474167 false --12-31 0001474167 2026-07-15 2026-07-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act o

Cosmos Health Inc.: Cosmos Health Share Buyback Surpasses $1 Million, Reaching 4.84 Million Shares; Continues Open Market Repurchases

Cosmos Health Inc. (NASDAQ:COSM) said it repurchased an additional 250,000 shares in the open market at an average price of about $0.2782 per share. Total repurchases under its up to $5 million program reached 4,838,000 shares for about $1.04 million. The program expires Dec. 31, 2026 and may continue subject to conditions.

Related tickers